JP2007238598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007238598A5 JP2007238598A5 JP2006307035A JP2006307035A JP2007238598A5 JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5 JP 2006307035 A JP2006307035 A JP 2006307035A JP 2006307035 A JP2006307035 A JP 2006307035A JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5
- Authority
- JP
- Japan
- Prior art keywords
- stroke
- patient
- composition
- composition according
- history
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006011 Stroke Diseases 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 3
- 125000004494 ethyl ester group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006307035A JP5069448B2 (ja) | 2006-02-07 | 2006-11-13 | 脳卒中再発予防用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006029954 | 2006-02-07 | ||
| JP2006029954 | 2006-02-07 | ||
| JP2006307035A JP5069448B2 (ja) | 2006-02-07 | 2006-11-13 | 脳卒中再発予防用組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006194043A Division JP4005104B2 (ja) | 2006-02-07 | 2006-07-14 | 脳卒中再発予防用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007238598A JP2007238598A (ja) | 2007-09-20 |
| JP2007238598A5 true JP2007238598A5 (enExample) | 2009-08-20 |
| JP5069448B2 JP5069448B2 (ja) | 2012-11-07 |
Family
ID=38584473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006307035A Active JP5069448B2 (ja) | 2006-02-07 | 2006-11-13 | 脳卒中再発予防用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5069448B2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| DK2424356T3 (en) | 2009-04-29 | 2017-12-04 | Amarin Pharmaceuticals Ie Ltd | STABLE PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR USING SAME |
| CA2759176C (en) | 2009-04-29 | 2016-03-15 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES3040261T3 (en) | 2012-06-29 | 2025-10-29 | Amarin Pharmaceuticals Ie Ltd | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| JP7020756B2 (ja) | 2018-09-24 | 2022-02-16 | アマリン ファーマシューティカルズ アイルランド リミテッド | 対象の心血管イベントのリスクを低減する方法 |
| KR20220122616A (ko) | 2019-11-12 | 2022-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심방 세동 및/또는 심방 조동을 갖는 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
-
2006
- 2006-11-13 JP JP2006307035A patent/JP5069448B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007238598A5 (enExample) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| ATE510537T1 (de) | Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit | |
| JP2012517449A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| FI3782612T3 (fi) | Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi | |
| IL191312A0 (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid | |
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| UA110012C2 (uk) | Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| HRP20151202T1 (hr) | Oralna formulacija metadoksina | |
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| NO20044547L (no) | Nye farmasoytiske sammensetninger inneholdende flibanserin | |
| MX2009004579A (es) | Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido. | |
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| JP2008266291A5 (enExample) | ||
| ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
| JP2009516719A5 (enExample) | ||
| WO2006062933A3 (en) | Stable compositions of fenofibrate with fatty acid esters | |
| JP2008539169A5 (enExample) | ||
| JP2006342148A5 (enExample) | ||
| JP2012097034A5 (enExample) | ||
| ATE534382T1 (de) | Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon |